<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00474994</url>
  </required_header>
  <id_info>
    <org_study_id>07-054</org_study_id>
    <secondary_id>P30CA008748</secondary_id>
    <secondary_id>MSKCC-07054</secondary_id>
    <secondary_id>PFIZER-MSKCC-07054</secondary_id>
    <nct_id>NCT00474994</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas</brief_title>
  <official_title>A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with&#xD;
      metastatic, locally advanced, or locally recurrent sarcomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate (complete response and partial response) in patients with&#xD;
           metastatic, locally advanced, or locally recurrent non-gastrointestinal stromal tumor&#xD;
           sarcomas treated with sunitinib malate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the 16- and 24-week progression-free survival rate (complete response, partial&#xD;
           response, and stable disease) in patients treated with this drug.&#xD;
&#xD;
        -  Determine the overall survival in patients treated with this drug.&#xD;
&#xD;
        -  Correlate clinical response with changes in soluble angiogenesis mediator levels in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the tumor maximum standardized uptake values by fludeoxyglucose F 18-PET scan&#xD;
           in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified by neoplastic subtype (vascular&#xD;
      connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans, chordoma, or&#xD;
      desmoid tumors vs high-grade undifferentiated pleomorphic sarcoma [i.e., malignant fibrous&#xD;
      histiocytoma (including myxofibrosarcoma)], or other nongastrointestinal connective tissue&#xD;
      tumors [including carcinosarcomas]).&#xD;
&#xD;
      Patients receive oral sunitinib malate once daily on days 1-28. Courses repeat every 4 weeks&#xD;
      in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Objective Response</measure>
    <time_frame>2 years</time_frame>
    <description>as assessed by RECIST criteria</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Adult Malignant Fibrous Histiocytoma of Bone</condition>
  <condition>Desmoid Tumor</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vascular connective tissue neoplasms, leiomyosarcoma, dermatofibrosarcoma protuberans (DFSP), desmoid tumors. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High grade undifferentiated pleomorphic sarcoma (includes the older designation malignant fibrous histiocytoma [MFH]) and other non-GIST connective tissue tumors; may include carcinosarcomas.Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chordomas. Sunitinib 37.5 mg daily continuously; one cycle is 28 days. Restaging: after every 2 cycles until after 6 cycles, when restaging will be decreased to once every 3 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed connective tissue neoplasm, including any of&#xD;
             the following neoplastic subtypes:&#xD;
&#xD;
               -  Vascular connective tissue neoplasms&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Dermatofibrosarcoma protuberans&#xD;
&#xD;
               -  Chordoma&#xD;
&#xD;
               -  Desmoid tumors&#xD;
&#xD;
               -  High-grade undifferentiated pleomorphic sarcoma (e.g., malignant fibrous&#xD;
                  histiocytoma [including myxofibrosarcoma])&#xD;
&#xD;
               -  Carcinosarcomas (e.g., malignant mixed Müllerian tumors)&#xD;
&#xD;
               -  Giant hemangiomata&#xD;
&#xD;
               -  Kaposi sarcoma&#xD;
&#xD;
          -  Metastatic, locally advanced, or locally recurrent disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Tumor lesions in a previously irradiated area may be considered measurable&#xD;
                  provided there is evidence of growth that cannot be attributed to necrosis or&#xD;
                  bleeding&#xD;
&#xD;
          -  No gastrointestinal stromal tumor sarcomas&#xD;
&#xD;
          -  Prior standard neoadjuvant or adjuvant systemic therapy required for patients with the&#xD;
             following diagnoses:&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing sarcoma&#xD;
&#xD;
          -  No untreated brain metastases, spinal cord compression, or evidence of symptomatic&#xD;
             brain metastases or leptomeningeal disease as documented on screening CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  PT and INR ≤ 1.5&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Calcium ≤ 12 mg/dL&#xD;
&#xD;
          -  Blood glucose &lt; 150 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to, during, and for 28 days&#xD;
             after completion of study therapy&#xD;
&#xD;
          -  Other malignancies allowed provided sarcoma is the primary disease requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Able to swallow oral medications&#xD;
&#xD;
          -  No other disease or illness within the past 6 months, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Severe or unstable angina&#xD;
&#xD;
               -  Coronary or peripheral artery bypass graft&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack&#xD;
&#xD;
               -  Pulmonary embolism&#xD;
&#xD;
          -  No evidence of a bleeding diathesis&#xD;
&#xD;
          -  No ongoing cardiac dysrhythmias &gt; grade 2&#xD;
&#xD;
          -  No uncontrolled hypertension, defined as blood pressure &gt; 150/100 mm Hg despite&#xD;
             optimal medical therapy&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 50% by echocardiogram or MUGA scan&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No pre-existing thyroid abnormality, defined as abnormal thyroid function tests&#xD;
             despite medication&#xD;
&#xD;
          -  No prolonged QTc interval (i.e., QTc &gt; 450 msec for males or QTc &gt; 470 msec for&#xD;
             females) on baseline EKG&#xD;
&#xD;
          -  No hemorrhage ≥ grade 3 in the past 4 weeks&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No prior sunitinib malate&#xD;
&#xD;
          -  No more than 3 prior cytotoxic chemotherapy regimens for metastatic disease&#xD;
&#xD;
               -  Adjuvant chemotherapy for sarcoma completed &gt; 1 year prior to study entry is not&#xD;
                  considered a line of prior treatment&#xD;
&#xD;
          -  At least 2 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior carmustine or mitomycin C&#xD;
&#xD;
          -  At least 1 week since prior biological therapy or small molecule kinase inhibitors&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy (except for palliative radiotherapy to&#xD;
             specific sites)&#xD;
&#xD;
               -  Prior palliative radiotherapy allowed provided it is considered medically&#xD;
                  necessary and there are other target lesions to assess&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  Concurrent major surgery allowed provided study drug is stopped 2 weeks before surgery&#xD;
             and resumed 2 weeks after surgery&#xD;
&#xD;
          -  Concurrent palliative radiotherapy (e.g., focal radiotherapy to a bony metastasis for&#xD;
             relieving bone pain) allowed&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation (e.g., warfarin)&#xD;
&#xD;
               -  Prophylactic anticoagulation (i.e., low-dose warfarin) of venous or arterial&#xD;
                  access devices allowed provided requirements for PT and INR are met&#xD;
&#xD;
          -  No other concurrent approved or investigational anticancer agents or treatment,&#xD;
             including chemotherapy, biological response modifier therapy, hormonal therapy, or&#xD;
             immunotherapy&#xD;
&#xD;
               -  Concurrent hormone replacement therapy for adrenal insufficiency allowed&#xD;
&#xD;
          -  No concurrent antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)&#xD;
&#xD;
          -  No concurrent rifampin, theophylline, ketoconazole, or Hypericum perforatum (St.&#xD;
             John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary L. Keohan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Maki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 1;27(19):3154-60. doi: 10.1200/JCO.2008.20.9890. Epub 2009 May 18.</citation>
    <PMID>19451429</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 16, 2007</study_first_submitted>
  <study_first_submitted_qc>May 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2007</study_first_posted>
  <results_first_submitted>December 15, 2015</results_first_submitted>
  <results_first_submitted_qc>December 15, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrosarcoma</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>localized adult malignant fibrous histiocytoma of bone</keyword>
  <keyword>metastatic adult malignant fibrous histiocytoma of bone</keyword>
  <keyword>recurrent adult malignant fibrous histiocytoma of bone</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent Kaposi sarcoma</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>dermatofibrosarcoma protuberans</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>stage III uterine sarcoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>desmoid tumor</keyword>
  <keyword>adult angiosarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>uterine carcinosarcoma</keyword>
  <keyword>endometrial stromal sarcoma</keyword>
  <keyword>fibrosarcomatous osteosarcoma</keyword>
  <keyword>chondrosarcomatous osteosarcoma</keyword>
  <keyword>adult alveolar soft-part sarcoma</keyword>
  <keyword>adult epithelioid sarcoma</keyword>
  <keyword>adult extraskeletal chondrosarcoma</keyword>
  <keyword>adult extraskeletal osteosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult malignant mesenchymoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>adult desmoplastic small round cell tumor</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>anaplastic osteosarcoma</keyword>
  <keyword>mixed osteosarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>osteoblastic osteosarcoma</keyword>
  <keyword>telangiectatic osteosarcoma</keyword>
  <keyword>classic Kaposi sarcoma</keyword>
  <keyword>immunosuppressive treatment related Kaposi sarcoma</keyword>
  <keyword>AIDS-related Kaposi sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Histiocytoma</mesh_term>
    <mesh_term>Histiocytoma, Benign Fibrous</mesh_term>
    <mesh_term>Histiocytoma, Malignant Fibrous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</title>
          <description>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patient Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient evaluable for toxicity only</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient found to be ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</title>
          <description>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Objective Response</title>
        <description>as assessed by RECIST criteria</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</title>
            <description>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Objective Response</title>
          <description>as assessed by RECIST criteria</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Partial Response (PR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression of Disease (POD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</title>
          <description>Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Ulcer, Duodenum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death not associated with CTCAE term- Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term-Disease progression NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/thrombus/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastrointestinal, other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (asthenia, lethargy, malaise)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Mucositis (Clincal exam)- Oral cavity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Bilirubin (hyperbilirubinemia)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash: hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mary Keohan</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-888-4160</phone>
      <email>KeohanM@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

